Active Ingredient History

  • Now
Plinabulin is a small molecule under development by BeyondSpring Pharmaceuticals, and is in a world-wide Phase 3 clinical trial for non-small cell lung cancer. Plinabulin is being investigated for the reduction of chemotherapy-induced neutropenia and for anti-cancer effects in combination with immune checkpoint inhibitors and in KRAS mutated tumors.   Wikipedia

  • SMILES: CC(C)(C)c1[nH]cnc1\C=C\2/NC(=O)\C(=C\c3ccccc3)\NC2=O
  • Mol. Mass: 336.4
  • ALogP: 0.74
  • ChEMBL Molecule:
More Chemistry
npi2358 | npi 2358 | npi-2358 | plinabulin


Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue